🔗 Permalink

Inventor profile of:

DAVID C. CIPOLLA

City:

San Ramon, California

Country:

United States

Published Applications:

Last publication date:

2021-01-14

Top Assignees for applications by DAVID C. CIPOLLA

The entities that hold a legal rights for patent applications filed by inventor CIPOLLA DAVID C.:

ARADIGM CORPORATION 19 Hayward, CA United States
OREGON STATE UNIVERSITY 4 Corvallis, OR United States
GRIFOLS, S.A. 3 Los Angeles, CA United States
OREGON STATE UNIVERSITY 1 Corvallis, CA United States

Recent patent applications by CIPOLLA DAVID C.

DAVID C. CIPOLLA from San Ramon, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2021-01-14

US20210007985A1

Human necessities

LIPOSOMAL ANTI-INFECTIVE FORMULATIONS TO INHIBIT NON-TUBERCULOUS MYCOBACTERIA (NTM) MICROAGGREGATE FORMATION AND ESTABLISHMENT OF NTM BIOFILM

#2 | 2020-10-15

US20200323845A1

Human necessities

Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria

#3 | 2020-09-24

US20200297722A1

Human necessities

pH-Modulated Formulations for Pulmonary Delivery

#4 | 2019-12-26

US20190388416A1

Human necessities

Concentrated, inhalable ciprofloxacin formulation

#5 | 2019-10-31

US20190328731A1

Human necessities

LIPOSOMAL CIPROFLOXACIN FORMULATIONS WITH ACTIVITY AGAINST NON-TUBERCULOUS MYCOBACTERIA

#6 | 2018-04-05

US20180092912A1

Human necessities

Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria

#7 | 2017-03-16

US20170071934A1

Human necessities

Liposomal ciprofloxacin formulations with encapsulated ciprofloxacin nanocrystals

#8 | 2017-02-09

US20170035753A1

Human necessities

Concentrated, inhalable ciprofloxacin formulation

#9 | 2016-11-17

US20160331744A1

Human necessities

pH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY

#10 | 2016-05-05

US20160120806A1

Human necessities

NANOCRYSTALS FORMED IN A MICROENVIRONMENT

#11 | 2015-10-08

US20150283133A1

Human necessities

Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria

#12 | 2015-10-08

US20150283076A1

Human necessities

Liposomal formulations that form drug nanocrystals after freeze-thaw

#13 | 2015-07-23

US20150202201A1

Human necessities

Concentrated, inhalable antibiotic formulation

#14 | 2015-04-23

US20150110855A1

Human necessities

Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile

#15 | 2015-03-12

US20150071992A1

Human necessities

Concentrated, inhalable antibiotic formulation

#16 | 2012-11-08

US20120282328A1

Human necessities

Dual action, inhaled formulations providing both an immediate and sustained release profile

#17 | 2012-09-27

US20120244206A1

Human necessities

Dual action, inhaled formulations providing both an immediate and sustained release profile

#18 | 2012-07-12

US20120177693A1

Human necessities

DEEP LUNG PULMONARY DELIVERY OF TREPROSTINIL

#19 | 2011-06-23

US20110150983A1

Human necessities

Concentrated, inhalable ciprofloxacin formulation

#20 | 2011-05-05

US20110104259A1

Human necessities

PROCESSES FOR TASTE-MASKING OF INHALED FORMULATIONS

#21 | 2011-03-17

US20110064796A1

Human necessities

Concentrated, inhalable antibiotic formulation

#22 | 2010-08-19

US20100209538A1

Human necessities

PH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY

#23 | 2009-11-05

US20090274754A1

Human necessities

Dual action, inhaled formulations providing both an immediate and sustained release profile

#24 | 2009-10-29

US20090269396A1

Human necessities

Dual action, inhaled formulations providing both an immediate and sustained release profile

#25 | 2008-06-12

US20080138397A1

Human necessities

PROCESSES FOR TASTE-MASKING OF INHALED FORMULATIONS

InventorID:

1095461 ⎘